| Project/Area Number |
06671274
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | KOBE UNIVERSITY |
|---|
Principal Investigator |
HAMABE Yutaka Kobe University School of Medicine, First Department of Surgery, Assistant Professor, 医学部附属病院, 助手 (30218549)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SAITOH Yoichi Kobe University School of Medicine, First Department of Surgery, Professor, 医学部附属病院, 教授 (90004803)
IKADA Yoshito Kyoto University, Research Center for Biomedical engineering, Professor, 教授 (00025909)
IKUTA Hajime Kobe University School of Medicine, First Department of Surgery, Medical Staff, 医学部附属病院, 医員
|
|---|
| Project Period (FY) |
1994 – 1996
|
| Project Status |
Completed (Fiscal Year 1996)
|
| Budget Amount *help |
¥2,000,000 (Direct Cost: ¥2,000,000)
Fiscal Year 1996: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1995: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1994: ¥600,000 (Direct Cost: ¥600,000)
|
|---|
| Keywords | Local chemotherapy / Lymphotropic delivery / CDDP / Microshrere / Esophageal cancer / VX2 carcinoma / 家兎VX2腫瘍 / Drug Delivery System |
|---|
| Research Abstract |
We developed a new treatment for local chemotherapy with glycolide-L-lactide copolymers incorporating CDDP (CDDP-MS) in an attempt to maximize tumor drug delivery and, at the same time, to minimize systemic toxicity. This study was designed to develop the treatment espcially for mediastinal metastatic lymphnodes of esophageal cancer. In the first year, with animal model using VX2 carcinoma we have shown that the level of Pt concentration of metastatic lymphnodes was high 4 day after intramediastinal administration of CDDP-MS and that of kidney was low, as compard with other treatments. In the second year, about anti-tumor effect the treatment exhibited marked effect at the metastatic lymphnodes in the histological findings and well suppression for proliferation of tumor cells in the labeling index. These results suggested that CDDP-MS showed the well lymphotropic delivery and sustained release with ecxellent anti-tumor effect. In the third year, we attempted the clinical pilot study that SDDP-MS was administrated into the mediastinum via catherter 2 weeks after the resection of esophageal cancer. Five patients with esophageal cancer were treated with this method and the Pt concentration in blood plasma were maintained at a low level for two weeks after administration. The side effects were well tolerated At this time, we cannot yet estimate the clinical results and we need more cases and long following duration. Based on these results, we conclude that our method offers an effective therapeutic option for patients with esophageal cancer.
|
